AVBP

Business Context and Reporting Period

Arrivent Biopharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on identifying, licensing, and globalizing biopharma innovations, primarily for oncology. The company's lead candidate is firmonertinib, a third-generation tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC). This Form 10-Q covers the quarterly period ended September 30, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the nine months ended September 30, 2025, increased by $70.9 million compared to the same period in 2024, driven primarily by higher R&D expenditures.
• R&D Expense Surge: R&D expenses rose $62.3 million year-over-year (YTD). This was largely due to a $40.0 million upfront payment for the ARR-217 license agreement with Lepu Biopharma and increased costs for the FURVENT Phase 3 clinical trial.
• Early-Stage Program Investment: Expenditures on early-stage programs increased by $42.1 million YTD, reflecting the new Lepu collaboration and other pipeline advancements.
• Capital Raising: The company raised significant capital in 2025, including $87.3 million via an "at-the-market" (ATM) program and $80.6 million from a July 2025 underwritten public offering (including pre-funded warrants).
• Share Count: Weighted-average shares outstanding increased from ~30.7 million (YTD 2024) to ~37.0 million (YTD 2025) due to equity issuances.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash and marketable securities ($305.4 million) are sufficient to fund operations for at least 12 months from the filing date.
• Clinical Progress:
  • Firmonertinib: Final data from the FURTHER trial (PACC mutations) showed a 16.0-month median progression-free survival. The company plans to initiate the ALPACCA Phase 3 trial in Q4 2025.
  • ARR-217: A new antibody drug conjugate for gastrointestinal cancers licensed from Lepu Biopharma in January 2025.
• Future Funding Needs: The company expects to continue incurring significant losses and will require additional capital to advance clinical trials and commercialization. Future funding may come from equity offerings, debt, or collaborations.
• Risks:
  • Dependence on the success of clinical trials for firmonertinib and ARR-217.
  • Need for additional financing; failure to raise capital could force delays or termination of programs.
  • Significant contingent milestone payments (up to $1.17 billion for Lepu and $765 million for Allist) if development and commercial milestones are met.

Key Facts for Investor Verification

• Runway: Verify the 12-month liquidity runway assumption against current burn rates and potential delays in clinical enrollment.
• Lepu Collaboration: Confirm the status of the $40 million upfront payment and the timeline for the next $6 million near-term milestone payment.
• ATM Program: Note that approximately $159.2 million remains available under the ATM program for future equity sales.
• Credit Facility: Verify the conditions required to draw the $75 million term loan from Silicon Valley Bank, as no amounts have been drawn to date.
• Dilution: Monitor the impact of the July 2025 offering (including 1.36 million pre-funded warrants) and future ATM sales on shareholder dilution.